H.C. Wainwright downgraded Kinnate Biopharma to Neutral from Buy without a price target after the company announced a pipeline reprioritization initiative and workforce reduction. The firm says several clinical-stage programs have been culled. It downgraded the shares after taking these developments into account.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KNTE:
- Kinnate Biopharma downgraded to Neutral on uncertainty at Piper Sandler
- Kinnate Biopharma downgraded to Neutral from Overweight at Piper Sandler
- Kinnate Biopharma trading resumes
- Kinnate Biopharma to reduce workforce by 70%, announces reprioritization plan
- Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring